Agarikon Index Sets New Standard for Psychedelic Medicine Data

Agarikon Index: A New Reference Layer for Psychedelic Medicine

Agarikon has launched the first rigorously screened, source-cited global index for the psychedelic medicine sector, providing a unified and auditable reference for clinics, clinical trials, researchers, legal frameworks, and industry actors. This development addresses a persistent challenge in the field: the fragmentation of critical information across disparate directories, registries, and legal databases. By integrating these layers and citing the source at every connection, Agarikon delivers a resource that is both comprehensive and verifiable, setting a new standard for transparency in psychedelic research and policy.

The current snapshot of Agarikon’s index covers approximately 2,564 treatment clinics, 282 retreats or legal-access points in dozens of countries, 1,619 registered clinical trials, 1,660 researchers with a publication corpus of 9,757 works, 173 organizations spanning funders, suppliers, trainers, insurers, and regulators, and 1,532 tracked state legislative bills. Each entry is tagged with legal-status classifications and, where applicable, cites the enabling statute—an approach that allows for granular legal due diligence and jurisdictional analysis, which has been notably absent in previous attempts at sector mapping.

How Agarikon Screens and Documents Its Data

Agarikon’s methodology is distinguished by its explicit, published screening process, which prioritizes accuracy over volume. Unlike scraped or crowd-sourced directories, Agarikon applies a multi-stage pipeline: relevance classification at data ingestion, validation at merging, and quarantine with a written reason for any exclusion before publication. Each exclusion is logged and shipped with the dataset, making the entire decision process auditable and transparent—a feature rarely seen in comparable health data indices.

The index sources its data from primary, authoritative repositories: ClinicalTrials.gov for clinical trials, U.S. Centers for Medicare & Medicaid Services (CMS) Open Payments and Medicare Part B for financial and claims data, Drug Enforcement Administration (DEA) quotas from the Federal Register, OpenAlex and PubMed for publications, and LegiScan for state legislation (licensed under Creative Commons BY 4.0, with attribution requirements). Clinic and retreat listings are aggregated from public directories and state licensing feeds, with legal-status tags and statute citations wherever possible. Notably, Agarikon does not silently drop records; instead, it retains and publishes the reason for exclusion, allowing users to audit the boundaries of the dataset.

Implications for Policy, Research, and Due Diligence

The availability of a screened, source-cited index has immediate implications for researchers, clinicians, policymakers, and investors. For the first time, stakeholders can trace the provenance of every data point—whether a clinic’s legal status, a trial’s registration, or a legislative bill’s jurisdiction—enabling more robust due diligence and policy analysis. This is particularly salient in the context of rapidly evolving state and federal laws, where legal ambiguity has hampered both clinical research and commercial planning.

For research planning, Agarikon’s integration of clinical trial registries with researcher profiles and publication metrics allows for network analysis of research activity and gaps. For policymakers, the ability to map clinics and legal-access points against enabling statutes supports evidence-based legislative design. For funders and industry actors, the index’s transparency around organizational roles and financial flows (via CMS Open Payments and other disclosures) provides a defensible starting point for risk assessment and compliance.

A non-obvious implication is the potential for Agarikon’s exclusion log to serve as a quality control benchmark for other health data projects. By making every exclusion reason public, Agarikon not only increases trust but also sets a precedent for methodological transparency that could pressure other directories and indices to adopt similar standards—especially as regulatory scrutiny of health data intensifies.

Risks, Limitations, and Unknowns

While Agarikon’s approach marks a significant advance, several risks and limitations remain. The clinics dataset, for example, is a screened aggregation from public directories and licensing feeds rather than independently verified field data. This means that while false positives are minimized, the absence of on-the-ground verification leaves open the possibility of outdated or incomplete records. Legal-status tagging is robust for retreat and legal-access points with mappable statutes, but less so for ordinary clinics operating under general medical law, where explicit psychedelic statutes are often absent.

Another challenge is the mixed licensing regime. While most government-sourced data is public domain, legislative data from LegiScan requires attribution, and some directory data may have reuse restrictions. Users must pay careful attention to per-record licensing, especially when integrating Agarikon data into derivative works or commercial products. Finally, the index’s value depends on its ongoing maintenance and update cycle; as the field evolves, so too must the methodologies for screening and validation to keep pace with new legal, clinical, and industry developments.

Looking Ahead: Toward a More Transparent Psychedelic Sector

Agarikon’s launch signals a maturation point for the psychedelic medicine sector, where due diligence, policy analysis, and research planning can now be grounded in a transparent, auditable data infrastructure. As regulatory frameworks continue to shift and the number of clinical trials and treatment centers grows, the need for such a reference layer will only increase. The index’s daily rebuilds and public change log offer a living record of the sector’s evolution, providing stakeholders with a tool to navigate complexity and uncertainty with greater confidence.

Ultimately, Agarikon’s methodology—especially its public exclusion log and per-record provenance—may become a model for other emerging fields where data integrity and regulatory compliance are paramount. Its success will depend on sustained transparency, methodological rigor, and responsiveness to the sector’s rapid changes.

How we research: This article was written and reviewed by Dr. Alex R. Greene, PhD (policy analysis, data science), on 2026-10-02. Primary sources: Agarikon launch record, Agarikon methodology and data, and cited government and registry sources.